OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Nuclear Medicine is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Performance Evaluation of the uEXPLORER Total-Body PET/CT Scanner Based on NEMA NU 2-2018 with Additional Tests to Characterize PET Scanners with a Long Axial Field of View	174
FAPI-74 PET/CT Using Either ¹⁸F-AlF or Cold-Kit ⁶⁸Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients	153
The Latest Developments in Imaging of Fibroblast Activation Protein	134
Incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region	129
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results	128
Performance Characteristics of the Biograph Vision Quadra PET/CT System with a Long Axial Field of View Using the NEMA NU 2-2018 Standard	117
Fibroblast Activation Protein–Targeted PET/CT with ⁶⁸Ga-FAPI for Imaging IgG4-Related Disease: Comparison to ¹⁸F-FDG PET/CT	105
Impact of ⁶⁸Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas	105
Design and Development of ^99mTc-Labeled FAPI Tracers for SPECT Imaging and ¹⁸⁸Re Therapy	103
Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients	101
A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies	93
Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an ¹⁸F-Labeled FAP Inhibitor	89
First Clinical Results for PSMA-Targeted α-Therapy Using ²²⁵Ac-PSMA-I&T in Advanced-mCRPC Patients	81
FAPI PET/CT: Will It End the Hegemony of ¹⁸F-FDG in Oncology?	78
⁶⁸Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership	74
Autoimmune Encephalitis Concomitant with SARS-CoV-2 Infection: Insight from ¹⁸F-FDG PET Imaging and Neuronal Autoantibodies	73
Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer	73
Diagnostic Evaluation of Pulmonary Embolism During the COVID-19 Pandemic	72
Diagnostic Accuracy of ¹⁸F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence	72
Deep-Learning ¹⁸F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma	70
Fibroblast Activation Protein–Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study	70
Correlation of ⁶⁸Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study	69
Neuroinflammation PET Imaging: Current Opinion and Future Directions	68
Semiautomatically Quantified Tumor Volume Using ⁶⁸Ga-PSMA-11 PET as a Biomarker for Survival in Patients with Advanced Prostate Cancer	68
Head-to-Head Evaluation of ¹⁸F-FES and ¹⁸F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer	66

Impact of ⁶⁸Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial	65
⁶⁸Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with ¹⁸F-FDG PET/CT	63
Phase I Trial of ¹³¹I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients	61
The Future of Nuclear Medicine, Molecular Imaging, and Theranostics	61
Neuropsychologic Profiles and Cerebral Glucose Metabolism in Neurocognitive Long COVID Syndrome	61
⁶⁸Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer	61
Determining Amyloid-β Positivity Using ¹⁸F-AZD4694 PET Imaging	60
Prostate-Specific Membrane Antigen Radioligand Therapy Using ¹⁷⁷Lu-PSMA I&T and ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of	60
Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences	58
First-in-Human Evaluation of ¹⁸F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A	58
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging	57
Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of ⁶⁸Ga-Labeled FAPI Dimer	55
⁶⁸Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the ⁶⁸Ga-FAPI PET Prospective Observational Trial	55
Targeted α-Emitter Therapy with ²¹²Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial	54
Pitfalls and Common Findings in ⁶⁸Ga-FAPI PET: A Pictorial Analysis	54
¹⁸F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging	54
OpenDose: Open-Access Resource for Nuclear Medicine Dosimetry	52
Production and Supply of α-Particle–Emitting Radionuclides for Targeted α-Therapy	52
Benefit of Improved Performance with State-of-the Art Digital PET/CT for Lesion Detection in Oncology	51
¹⁸F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study	50
First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients	50
Initial clinical experience with ⁹⁰Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients	50
Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium	50
Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy	49
SNMMI Procedure Standard/EANM Practice Guideline on Pediatric¹⁸F-FDG PET/CT for Oncology 1.0	49
Global Impact of COVID-19 on Nuclear Medicine Departments: An International Survey in April 2020	48
Total-Body Quantitative Parametric Imaging of Early Kinetics of ¹⁸F-FDG	48
SPECT/CT: Standing on the Shoulders of Giants, It Is Time to Reach for the Sky!	48
Optical Imaging Modalities: Principles and Applications in Preclinical Research and Clinical Settings	47
Imaging of Pheochromocytoma and Paraganglioma	46
Absolute Quantitation of Cardiac ^99mTc-Pyrophosphate Using Cadmium-Zinc-Telluride–Based SPECT/CT	44
COVID-19 mRNA Vaccination: Age and Immune Status and Its Association with Axillary Lymph Node PET/CT Uptake	44
Peptide Receptor Radionuclide Therapy with ⁶⁷Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model	43
Nuclear Imaging of Bacterial Infection: The State of the Art and Future Directions	42
Prognostic Value of ¹⁸F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy	42
First-in-Humans Study of the SSTR Antagonist ¹⁷⁷Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy	42
Combination Strategies to Improve Targeted Radionuclide Therapy	40
Study of ⁸⁹Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer	40
Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET: Myth or Reality?	40
First-in-Humans Application of ¹⁶¹Tb: A Feasibility Study Using ¹⁶¹Tb-DOTATOC	40
Head-to-Head Comparison of ⁶⁸Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary P	39
Immune-Checkpoint Blockade Enhances ²²⁵Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer	39
Quantitative ⁶⁸Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with ¹⁷⁷Lu-DOTATATE	39
Phase I Study of ^99mTc-ADAPT6, a Scaffold Protein–Based Probe for Visualization of HER2 Expression in Breast Cancer	39
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of ⁸⁹Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody	38
When Does Physician Use of AI Increase Liability?	38
Molecular Imaging Findings on Acute and Long-Term Effects of COVID-19 on the Brain: A Systematic Review	38
Somatostatin Receptor–Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis	37
Direct Comparison of the Tau PET Tracers¹⁸F-Flortaucipir and¹⁸F-MK-6240 in Human Subjects	37
The Role of ⁸⁹Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals	37

PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer	36
Data-Driven Respiratory Gating Outperforms Device-Based Gating for Clinical ¹⁸F-FDG PET/CT	36
Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with ¹⁷⁷Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort	36
⁶⁸Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma	36
¹⁷⁷Lu-Labeled Albumin-Binder–Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio	36
Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling	36
Detecting Fibroblast Activation Proteins in Lymphoma Using ⁶⁸Ga-FAPI PET/CT	35
Molecular Imaging of Bone Metastases and Their Response to Therapy	35
Matched-Pair Comparison of ⁶⁸Ga-PSMA-11 and ¹⁸F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non–Tumor-Related Uptake and	35
Appropriate Use Criteria for PET Myocardial Perfusion Imaging	35
Nuclear Medicine and Artificial Intelligence: Best Practices for Algorithm Development	35
Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer	34
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT	34
Dose–Response and Dose–Toxicity Relationships for Glass ⁹⁰Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer	34
Repurposing Molecular Imaging and Sensing for Cancer Image–Guided Surgery	34
Direct Attenuation Correction Using Deep Learning for Cardiac SPECT: A Feasibility Study	33
Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with MR Tissue Characterization and Subsequent Functional Outcome	33
Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer ¹⁸F-BMS-986192	33
Dose–Effect Relationships of ¹⁶⁶Ho Radioembolization in Colorectal Cancer	32
Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects	32
Nuclear Medicine and Artificial Intelligence: Best Practices for Evaluation (the RELAINCE Guidelines)	32
First-in-Human Assessment of ¹¹C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer	31
Folate Receptor β–Targeted PET Imaging of Macrophages in Autoimmune Myocarditis	31
Harnessing α-Emitting Radionuclides for Therapy: Radiolabeling Method Review	31
Machine Learning with ¹⁸F-Sodium Fluoride PET and Quantitative Plaque Analysis on CT Angiography for the Future Risk of Myocardial Infarction	31
Whole-Body Parametric Imaging of ¹⁸F-FDG PET Using uEXPLORER with Reduced Scanning Time	31
The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review	31
Quantification of Macrophage-Driven Inflammation During Myocardial Infarction with ¹⁸F-LW223, a Novel TSPO Radiotracer with Binding Independent of the rs6971 Human Polymorphism	31
¹²⁴I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma	31
Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with ¹⁷⁷Lu-PSMA Therapy: A Multicenter Retrospective Analysis	30
Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of ¹⁸F-FDG PET/CT	30
CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma	30
Targeted PET Imaging of Chemokine Receptor 2–Positive Monocytes and Macrophages in the Injured Heart	30
Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network	30
A Novel Time–Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After ¹⁷⁷Lu-DOTATATE	30
¹⁷⁷Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer	29
First-in-Humans Evaluation of ¹⁸F-SMBT-1, a Novel ¹⁸F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis	29
The Added Value of ⁶⁸Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with ¹⁸F-FDG–Negative Findings	29
¹⁸F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study	29
Cyclotron Production and Separation of Scandium Radionuclides from Natural Titanium Metal and Titanium Dioxide Targets	28
Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy	28
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns	28
¹⁸F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study	27
Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUV_max Method	27
Photoacoustic Molecular Imaging for the Identification of Lymph Node Metastasis in Head and Neck Cancer Using an Anti-EGFR Antibody–Dye Conjugate	27
PET Tracing of Biodistribution for Orally Administered ⁶⁴Cu-Labeled Polystyrene in Mice	27
The Changing Face of Nuclear Cardiology: Guiding Cardiovascular Care Toward Molecular Medicine	27
Feasibility of single-time-point dosimetry for radiopharmaceutical therapies	27
Assessing Reactive Astrogliosis with ¹⁸F-SMBT-1 Across the Alzheimer Disease Spectrum	27
An Improved ²¹¹At-Labeled Agent for PSMA-Targeted α-Therapy	27
¹⁸F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies	26
Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade	26
Imaging of Synaptic Density in Neurodegenerative Disorders	26
Diagnostic Performance and Clinical Impact of ⁶⁸Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)	26
Conditional Generative Adversarial Networks Aided Motion Correction of Dynamic ¹⁸F-FDG PET Brain Studies	26
⁶⁴Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection	26
The Added Value of ¹⁸F-FDG PET/CT Compared with ⁶⁸Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer	26
Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with¹⁷⁷Lu-DOTATATE	26
Fluorescence-Guided Visualization of Soft-Tissue Sarcomas by Targeting Vascular Endothelial Growth Factor A: A Phase 1 Single-Center Clinical Trial	26
Tau PET Imaging in Neurodegenerative Disorders	26
MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of ⁶⁸Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients	26
Treatment Monitoring of Immunotherapy and Targeted Therapy Using ¹⁸F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences	25
Brain Tau Imaging: Food and Drug Administration Approval of ¹⁸F-Flortaucipir Injection	25
NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with ⁹⁰Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma	25
Head-to-Head Comparison of ⁶⁸Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients	25
Ultra-Fast List-Mode Reconstruction of Short PET Frames and Example Applications	25
Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant ¹⁷⁷Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors	25
Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using ⁶⁸Ga-PentixaFor PET	24
Combination of Forced Diuresis with Additional Late Imaging in ⁶⁸Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake	24
Phase I Trial of ^99mTc-(HE)₃-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer	24
Matched-Pair Comparison of ¹⁸F-DCFPyL PET/CT and ¹⁸F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions	24
Interim PET in Diffuse Large B-Cell Lymphoma	24
The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study	24
Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study	23
Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial	23
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors	23
Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted ¹⁸F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer St	23
Bone Mineral Density: Clinical Relevance and Quantitative Assessment	23
Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients Receiving Concomitant²²⁵Ac-DOTATATE–Targeted α-Therapy and Capecitabine: A Real-World-Scenario Managemen	23
PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using⁶⁸Ga-FAP-2286: Comparison with¹⁸F-FDG and⁶⁸Ga-FAPI-46 in a Single-Center, Prospective Stud	23

Molecular Imaging of Cardiac Amyloidosis	23
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study	23
aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in ¹⁸F-DCFPyL Images of Veterans with Prostate Cancer	23
Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker	23
Head-to-Head Comparison of ⁶⁸Ga-FAPI-46 and ¹⁸F-FDG PET/CT for Evaluation of Head and Neck Squamous Cell Carcinoma: A Single-Center Exploratory Study	22
Fully Automated, Semantic Segmentation of Whole-Body¹⁸F-FDG PET/CT Images Based on Data-Centric Artificial Intelligence	22
Moving Toward Multicenter Therapeutic Trials in Amyotrophic Lateral Sclerosis: Feasibility of Data Pooling Using Different Translocator Protein PET Radioligands	22
Integrity of Neurocognitive Networks in Dementing Disorders as Measured with Simultaneous PET/Functional MRI	22
Deep-Learning Generation of Synthetic Intermediate Projections Improves ¹⁷⁷Lu SPECT Images Reconstructed with Sparsely Acquired Projections	22
Early treatment response assessment using ¹⁸F-FET PET compared to contrast-enhanced MRI in glioma patients following adjuvant temozolomide chemotherapy	22
⁸⁹Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression	22
Feasibility of Acquisitions Using Total-Body PET/CT with an Ultra-Low ¹⁸F-FDG Activity	22
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.	22
Value of¹⁸F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study	21
An Opinion on ChatGPT in Health Care—Written by Humans Only	21
Imaging Neuroinflammation in Neurodegenerative Disorders	21
Assessment and Comparison of ¹⁸F-Fluorocholine PET and ^99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis	21
Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer	21
A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of ⁶⁸Ga-NODAGA-LM3 and ⁶⁸Ga-DOTA-LM3 in Patients with Well-Differentiated Neu	21
Summary: Appropriate Use Criteria for Estrogen Receptor–Targeted PET Imaging with 16α-¹⁸F-Fluoro-17β-Fluoroestradiol	21
Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer	21
Investigating Low-Dose Image Quality in Whole-Body Pediatric ¹⁸F-FDG Scans Using Time-of-Flight PET/MRI	21
Assessing Response to ¹⁷⁷Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria	21
Disparities in PET Imaging for Prostate Cancer at a Tertiary Academic Medical Center	21
Noninvasive Evaluation of CD20 Expression Using ⁶⁴Cu-Labeled F(ab′)₂ Fragments of Obinutuzumab in Lymphoma	20
Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study	20
A Comprehensive Assessment of ⁶⁸Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients	20
The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders, Part 1: Hyperthyroidism	20
What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies	20
The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in ¹⁸F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma	20
Ferronostics: Measuring Tumoral Ferrous Iron with PET to Predict Sensitivity to Iron-Targeted Cancer Therapies	20
Management of Differentiated Thyroid Cancer: The Standard of Care	20
Safety, Biodistribution, and Radiation Dosimetry of ¹⁸F-rhPSMA-7.3 in Healthy Adult Volunteers	20
PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders	20
A Microdosing Study with ^99mTc-PHC-102 for the SPECT/CT Imaging of Primary and Metastatic Lesions in Renal Cell Carcinoma Patients	20
¹⁸F-AlF-NOTA-Octreotide Outperforms⁶⁸Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study	19
Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer	19
At Last, ¹⁸F-FDG for Inflammation and Infection!	19
Response evaluation and survival prediction following PD-1 immunotherapy in patients with non-small-cell lung cancer: comparison of assessment methods.	19
First Tau PET Tracer Approved: Toward Accurate In Vivo Diagnosis of Alzheimer Disease	19
Semiautomatic Tumor Delineation for Evaluation of ⁶⁴Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume	19
Simplified Quantification of ¹¹C-UCB-J PET Evaluated in a Large Human Cohort	19
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with ¹⁸F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Singl	19
How Much Can Potential Jurors Tell Us About Liability for Medical Artificial Intelligence?	19
Dynamic ⁶⁸Ga-PSMA-11 PET/CT for the Primary Evaluation of Localized Renal Mass: A Prospective Study	19
Asymmetry of Fibrillar Plaque Burden in Amyloid Mouse Models	19
Preclinical Development of ¹⁸F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-d-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis	19
¹⁷⁷Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial	19
mCRPC Patients Receiving ²²⁵Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis	19
Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3	19
Statistical Considerations in the Evaluation of Continuous Biomarkers	18
PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study	18
⁶⁸Ga-NODAGA-Exendin-4 PET/CT Improves the Detection of Focal Congenital Hyperinsulinism	18
⁶⁸Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy	18
The Role of Nuclear Medicine for COVID-19: Time to Act Now	18
PET Imaging of the Natural Killer Cell Activation Receptor NKp30	18
Who Was the First Doctor to Report the COVID-19 Outbreak in Wuhan, China?	18
Dynamic ¹⁸F-FPCIT PET: Quantification of Parkinson Disease Metabolic Networks and Nigrostriatal Dopaminergic Dysfunction in a Single Imaging Session	18
Repetitive Early⁶⁸Ga-FAPI PET Acquisition Comparing⁶⁸Ga-FAPI-02,⁶⁸Ga-FAPI-46, and⁶⁸Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Infla	18
Cyclotron produced ¹³²La as a PET imaging surrogate of therapeutic ²²⁵Ac	18
Synthesis and Preclinical Evaluation of a ⁶⁸Ga-Labeled Adnectin, ⁶⁸Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression	18
Efficacy and Safety of ¹⁷⁷Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study	18
A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake	18
α_vβ₆-Targeted Molecular PET/CT Imaging of the Lungs After SARS-CoV-2 Infection	18
¹¹C-PiB and¹²⁴I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention	18
Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls	17
One-Stop Shop: ¹⁸F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases	17
Preclinical evaluation of ²¹³Bi-/²²⁵Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer	17
Lessons Learned from Post–COVID-19 Vaccination PET/CT Studies	17
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma	17
¹⁸F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients	17
Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources	17
Dopaminergic Nigrostriatal Connectivity in Early Parkinson Disease: In Vivo Neuroimaging Study of ¹¹C-DTBZ PET Combined with Correlational Tractography	17
Comparison of the Effect of Three Different Dietary Modifications on Myocardial Suppression in ¹⁸F-FDG PET/CT Evaluation of Patients for Suspected Cardiac Sarcoidosis	17
Impact of ¹⁸F-FET PET/MRI on Clinical Management of Brain Tumor Patients	17
Evaluation of Safety and Dosimetry of ¹⁷⁷Lu-DOTA-ZOL for Therapy of Bone Metastases	17
¹⁷⁷Lu-Prostate-Specific Membrane Antigen Ligand After ²²³Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience	17
Radiation Dosimetry of ^99mTc-PSMA I&S: A Single-Center Prospective Study	17
¹⁸F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer	17
Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders	16
An ⁸⁹Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients	16
FAPI PET Opens a New Window to Understanding Immune-Mediated Inflammatory Diseases	16
Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?	16
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities	16
First In Vivo and Phantom Imaging of Cyclotron-Produced ¹³³La as a Theranostic Radionuclide for ²²⁵Ac and ¹³⁵La	16
Substitution of l-Tryptophan by α-Methyl-l-Tryptophan in ¹⁷⁷Lu-RM2 Results in ¹⁷⁷Lu-AMTG, a High-Affinity Gastrin-Releasing Peptide Receptor Ligand with Improved In Vivo S	16
Striatal Acetylcholine–Dopamine Imbalance in Parkinson Disease: In Vivo Neuroimaging Study with Dual-Tracer PET and Dopaminergic PET–Informed Correlational Tractography	16
Radionuclide Therapy in Prostate Cancer: From Standalone to Combination PSMA Theranostics	16
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study	16
Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model	16
Artificial Intelligence for PET Image Reconstruction	16
Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents	16
c-MET Receptor–Targeted Fluorescence on the Road to Image-Guided Surgery in Penile Squamous Cell Carcinoma Patients	15
Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using ¹⁹F/¹⁷⁷Lu-rhPSMA-7.3 and ¹⁷⁷Lu-PSMA I	15
Staging Liver Fibrosis by Fibroblast Activation Protein Inhibitor PET in a Human-Sized Swine Model	15